Advertisement

Commentary: Do surgeons believe treating atrial fibrillation improves survival yet?

      Concomitant surgical ablation performed with bioprosthetic valve implantation is safe, effective and improves survival; is it time for a randomized prospective study?
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Melo J
        • Santiago T
        • Aguiar C
        • et al.
        Surgery for atrial fibrillation in patients with mitral valve disease: results at five years from the International Registry of Atrial Fibrillation Surgery.
        J Thorac Cardiovasc Surg. 2008; 135 (PMID: 18374769): 863-869
        • Pyo WK
        • Kim HJ
        • Kim JB
        Does surgical ablation of atrial fibrillation benefit patients undergoing bioprosthetic valve replacement?.
        Semin Thorac Cardiovasc Surg. 2022; 34: 906-915
        • Badhwar V
        • Rankin JS
        • Ad N
        • et al.
        Surgical ablation of atrial fibrillation in the United States: trends and propensity matched outcomes.
        Ann Thorac Surg. 2017; 104 (PMID: 28669501): 493-500
        • Musharbash FN
        • Schill MR
        • Sinn LA
        • et al.
        Performance of the Cox-maze IV procedure is associated with improved long-term survival in patients with atrial fibrillation undergoing cardiac surgery.
        J Thorac Cardiovasc Surg. 2018; 155 (dPMID: 29056264): 159-170
        • Lee R
        • McCarthy PM
        • Wang EC
        • et al.
        Midterm survival in patients treated for atrial fibrillation: a propensity-matched comparison to patients without a history of atrial fibrillation.
        J Thorac Cardiovasc Surg. 2012; 143 (discussion 1350-1. PMID: 22465031): 1341-1351
        • Badhwar V
        • Rankin JS
        • Damiano RJ
        • et al.
        The society of thoracic surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation.
        Ann Thorac Surg. 2017; 103 (PMID: 28007240): 329-341
        • Ad N
        • Damiano RJ
        • Badhwar V
        • et al.
        Expert consensus guidelines: examining surgical ablation for atrial fibrillation.
        J Thorac Cardiovasc Surg. 2017; 153 (e1 PMID: 28390766): 1330-1354

      Linked Article

      • Does Surgical Ablation of Atrial Fibrillation Benefit Patients Undergoing Bioprosthetic Valve Replacement?
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          The benefit of avoiding lifelong anticoagulation therapy in patients with bioprosthetic heart valve implantation may potentially be offset by atrial fibrillation (AF); however, clinical impact of surgical AF ablation in such patients remains controversial. We enrolled 426 patients (aged 72.0 ± 7.8 years) with AF who underwent left-side valve replacement with bioprostheses between 2001 and 2018. Of these, 297 underwent concomitant surgical ablation (ablation group) and 129 underwent valve replacement alone (non-ablation group).
        • Full-Text
        • PDF